The Kihealth InterceptIQ™ platform is designed to generate biological intelligence across prevention, clinical care, therapeutic innovation, research, and population health.
Kihealth's proprietary Intercept IQ™ platform was designed to generate biological intelligence across prevention, clinical care, research, and therapeutic innovation.
The Kihealth platform is designed to help identify biological signals associated with metabolic dysfunction before traditional markers become abnormal.
"The future of healthcare begins before symptoms appear."
Providing physicians with deeper biological information to support earlier and more informed care decisions.
Advanced diagnostics can help identify, stratify, and monitor patient populations participating in clinical studies.
As precision medicine advances, diagnostics become increasingly important in identifying patients, supporting clinical development, and evaluating biological response.
"Tomorrow's therapies require tomorrow's diagnostics."
The rapid growth of metabolic therapeutics creates demand for objective biological measurements beyond traditional metrics.
Repeated testing allows healthcare providers and researchers to monitor biological trends over time rather than relying on isolated measurements.
The Intercept IQ™ platform was designed as a scalable molecular diagnostic architecture capable of supporting future disease applications and expanded clinical utility.
Kihealth is building more than a diagnostic test. We are developing a platform designed to generate biological intelligence across prevention, clinical care, therapeutic innovation, research, and population health.
"The future of healthcare will be driven by earlier detection, deeper biological insight, and more informed decision-making. Kihealth intends to help power that future."
Combining molecular biomarkers, beta cell biology, autoimmunity, and predictive analytics to identify children at elevated risk for Type 1 diabetes before clinical onset.
Kihealth's proprietary molecular and metabolic markers track beta cell stress, secretory reserve, and glycemic burden in a single longitudinal view.
Quantifies active beta cell injury and apoptosis through unmethylated insulin gene cfDNA — a direct molecular readout of islet stress.
Primary hormone of glucose homeostasis. Paired with C-peptide to distinguish endogenous secretion from exogenous influences.
Co-secreted with insulin in 1:1 ratio. Reflects residual beta cell functional capacity and tracks decline through disease progression.
Integrated 90-day glycemic exposure. Trends upward as beta cell function declines, often before fasting glucose becomes abnormal.
The major Type 1 diabetes autoantibodies. Multiple positivity defines Stage 1 T1D and complements molecular β-cell injury measurements.
Autoantibody serology defines who is on the path to T1D. BetaIntercept™ adds when — quantifying active β-cell injury in real time.
The Intercept Score™ combines molecular biomarkers, β-cell injury, metabolic markers, and autoimmune signatures into a single integrated assessment designed to support earlier understanding of Type 1 diabetes risk.
No single biomarker tells the complete story. The Intercept Score integrates multiple biological signals to build a more comprehensive view of risk.
Illustrative weighting. The Intercept Score™ is an evolving research framework — not a validated clinical decision tool. Performance characteristics are being established through ongoing studies.
T1D unfolds across years. Select a stage to see which biomarkers become informative — and where Kihealth's molecular signal extends the window for intervention.
Seroconversion to one or more islet autoantibodies. Multi-autoantibody positivity defines Stage 1 T1D.
Kihealth is evaluating how multiple biological signals may be integrated into a comprehensive disease interception framework — informed by preclinical and clinical research efforts.
Quantifying β-cell death dynamics through methylation-specific cfDNA assays across pediatric cohorts.
Characterizing seroconversion timing and titer trajectories alongside molecular injury signals.
Mapping how C-peptide, HbA1c, and insulin dynamics evolve across the T1D continuum.
Longitudinal modeling of stage transitions and time-to-clinical-onset across at-risk populations.
Integrating molecular, immune, metabolic, and clinical features into the evolving Intercept Score™.
Partnering with academic and clinical research networks to evaluate analytical and clinical performance.
Research use only · Not for clinical decision-making · Illustrative values shown
